FIBROGEN, INC. AND , AS WARRANT AGENT FORM OF PREFERRED STOCK WARRANT AGREEMENT DATED AS OFPreferred Stock Warrant Agreement • March 2nd, 2020 • Fibrogen Inc • Pharmaceutical preparations • New York
THIS PREFERRED STOCK WARRANT AGREEMENT (this “Agreement”), dated as of [●], between FIBROGEN, INC., a Delaware corporation (the “Company”), and [●], a [corporation] [national banking association] organized and existing under the laws of [●] and having a corporate trust office in [●], as warrant agent (the “Warrant Agent”).
FIBROGEN, INC. AND , AS WARRANT AGENT FORM OF COMMON STOCK WARRANT AGREEMENT DATED AS OFCommon Stock Warrant Agreement • March 2nd, 2020 • Fibrogen Inc • Pharmaceutical preparations • New York
THIS COMMON STOCK WARRANT AGREEMENT (this “Agreement”), dated as of [●], between FIBROGEN, INC., a Delaware corporation (the “Company”), and [●], a [corporation] [national banking association] organized and existing under the laws of [●] and having a corporate trust office in [●], as warrant agent (the “Warrant Agent”).
FIBROGEN, INC. AND , AS WARRANT AGENT FORM OF DEBT SECURITIES WARRANT AGREEMENT DATED AS OFWarrant Agreement • March 2nd, 2020 • Fibrogen Inc • Pharmaceutical preparations • New York
THIS DEBT SECURITIES WARRANT AGREEMENT (this “Agreement”), dated as of [●], between FIBROGEN, INC., a Delaware corporation (the “Company”), and [●], a [corporation] [national banking association] organized and existing under the laws of [●] and having a corporate trust office in [●], as warrant agent (the “Warrant Agent”).
FibroGen, Inc. Common Stock, par value $0.01 per share Underwriting AgreementUnderwriting Agreement • August 16th, 2017 • Fibrogen Inc • Pharmaceutical preparations • New York
FibroGen, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated in this Agreement (this “Agreement”), to issue and sell to the Underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of 8,000,000 shares (the “Firm Shares”) and, at the election of the Underwriters, up to 1,200,000 additional shares (the “Optional Shares”), of Common Stock, par value $0.01 per share (the “Stock”) of the Company. The Firm Shares and the Optional Shares that the Underwriters elect to purchase pursuant to Section 2 hereof being collectively called the “Shares”.
FIBROGEN, INC. AND , AS WARRANT AGENT FORM OF COMMON STOCK WARRANT AGREEMENT DATED AS OF [ ], 20Warrant Agreement • March 1st, 2017 • Fibrogen Inc • Pharmaceutical preparations • New York
This COMMON STOCK WARRANT AGREEMENT (this “Agreement”), dated as of between FIBROGEN, INC., a Delaware corporation (the “Company”), and , a [corporation] [national banking association] organized and existing under the laws of and having a corporate trust office in , as warrant agent (the “Warrant Agent”).
FIBROGEN, INC. Common Stock ($0.01 par value) Having an Aggregate Offering Price of up to $200 Million Equity Distribution AgreementEquity Distribution Agreement • August 8th, 2022 • Fibrogen Inc • Pharmaceutical preparations • New York
FibroGen, Inc., a Delaware corporation (the “Company”) confirms its agreement (this “Agreement”) with Goldman, Sachs & Co. LLC (the “Manager”) as follows:
INDEMNITY AGREEMENTIndemnification Agreement • October 23rd, 2014 • Fibrogen Inc • Pharmaceutical preparations • Delaware
THIS INDEMNITY AGREEMENT (this “Agreement”) dated as of , 20 , is made by and between FIBROGEN, INC., a Delaware corporation (the “Company”), and (“Indemnitee”).
fibrogen, inc. Common Stock ($0.01 par value) Having an Aggregate Offering Price of up to $200 Million Amended and Restated Equity Distribution AgreementEquity Distribution Agreement • February 27th, 2023 • Fibrogen Inc • Pharmaceutical preparations • New York
Reference is made to the Equity Distribution Agreement, dated August 8, 2022 (the “Original Agreement”), by and between FibroGen, Inc., a Delaware corporation (the “Company”) and Goldman Sachs & Co. LLC (the “Existing Manager”).
FIBROGEN, INC. CHANGE IN CONTROL AND SEVERANCE AGREEMENTChange in Control and Severance Agreement • October 24th, 2014 • Fibrogen Inc • Pharmaceutical preparations • California
This Change in Control and Severance Agreement (this “Agreement”) is dated as of [ ], 2014, by and between [ ] (“Executive”) and Fibrogen, Inc., a Delaware corporation (the “Company”). This Agreement is intended to provide Executive with certain benefits described herein upon the occurrence of specific events.
ContractWarrant Agreement • October 1st, 2014 • Fibrogen Inc • Pharmaceutical preparations • California
THIS WARRANT HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF l933 AS AMENDED. NO SALE OR DISPOSITION MAY BE EFFECTED EXCEPT IN COMPLIANCE WITH RULE 144 UNDER SAID ACT OR WITHOUT AN EFFECTIVE REGISTRATION STATEMENT RELATED THERETO OR AN OPINION OF COUNSEL FOR THE HOLDER, SATISFACTORY TO THE COMPANY, THAT SUCH REGISTRATION IS NOT REQUIRED UNDER THE ACT OR RECEIPT OF A NO-ACTION LETTER FROM THE SECURITIES AND EXCHANGE COMMISSION.
AMENDED AND RESTATED LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT (for the US and Certain Other Territories) between FIBROGEN, INC. and ASTRAZENECA ABLicense, Development and Commercialization Agreement • December 14th, 2017 • Fibrogen Inc • Pharmaceutical preparations • Beijing
[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Act of 1934, as amended.
CHANGE IN CONTROL AND SEVERANCE AGREEMENTChange in Control and Severance Agreement • May 8th, 2023 • Fibrogen Inc • Pharmaceutical preparations • California
This Change in Control and Severance Agreement (this “Agreement”) is dated as of __________, 20__ (the “Effective Date”), by and between [______________] (“Executive”) and FibroGen, Inc., a Delaware corporation (the “Company”). This Agreement is intended to provide Executive with certain benefits described herein upon the occurrence of specific events.
AMENDED AND RESTATED EXCLUSIVE LICENSE AGREEMENT by and among FIBROGEN, INC. and its AFFILIATES and ELUMINEX BIOSCIENCES (SUZHOU) LIMITEDExclusive License Agreement • August 7th, 2023 • Fibrogen Inc • Pharmaceutical preparations • New York
This SECOND AMENDED AND RESTATED EXCLUSIVE LICENSE AGREEMENT (this “Agreement”) is entered into April 19, 2023 (the “Second Restated License Execution Date”) and effective as of the Effective Date (as defined in Section 1.35), by and among: FIBROGEN, INC., a company organized under the laws of Delaware with a business address at 409 Illinois Street, San Francisco, CA 94158, United States and its Affiliates, including FibroGen (China) Medical Technology Development Co., Ltd. 珐博进（中国）医药技术开发有限公司, a wholly foreign owned limited liability company having its principal place of business at 101-601, Unit 2, Building 7, No. 88, 6th Ke Chuang Street, Beijing Economic Technological Development Area, Beijing, China (“FibroGen China”) (FIBROGEN, INC. and its Affiliates along with FibroGen China are collectively referred to herein as “FIBROGEN”), and ELUMINEX BIOSCIENCES (SUZHOU) LIMITED 典晶生物医药科技（苏州）有限公司, a company organized under the laws of People’s Republic of China with registered address at Unit
ContractWarrant Agreement • June 11th, 2014 • Fibrogen Inc • Pharmaceutical preparations • California
THIS WARRANT HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933 AS AMENDED. NO SALE OR DISPOSITION MAY BE EFFECTED EXCEPT IN COMPLIANCE WITH RULE 144 UNDER SAID ACT OR WITHOUT AN EFFECTIVE REGISTRATION STATEMENT RELATED THERETO OR AN OPINION OF COUNSEL FOR THE HOLDER, SATISFACTORY TO THE COMPANY, THAT SUCH REGISTRATION IS NOT REQUIRED UNDER THE ACT OR RECEIPT OF A NO-ACTION LETTER FROM THE SECURITIES AND EXCHANGE COMMISSION.
FIBROGEN – ASTELLAS Anemia License and Collaboration AgreementAnemia License and Collaboration Agreement • October 1st, 2014 • Fibrogen Inc • Pharmaceutical preparations
This Anemia License and Collaboration Agreement (“Agreement”) is made and entered into, effective as April 28, 2006 (“Effective Date”), by and between Astellas Pharma Inc., having a principal place of business at 3-11, Nihonbashi-Honcho 2-chome, Chuo-ku, Tokyo 103-8411, Japan (“Astellas”) and FibroGen, Inc., having a principal place of business at 225 Gateway Boulevard, South San Francisco, California 94080 U.S.A. (“FibroGen”).
COMMON STOCK PURCHASE AGREEMENTCommon Stock Purchase Agreement • October 24th, 2014 • Fibrogen Inc • Pharmaceutical preparations • California
THIS COMMON STOCK PURCHASE AGREEMENT (this “Agreement”) is dated as of October 20, 2014, by and among FibroGen, Inc., a Delaware corporation (the “Company”), and AstraZeneca AB, a company incorporated in Sweden (the “Purchaser”).
RESEARCH AND COMMERCIALIZATION AGREEMENTResearch and Commercialization Agreement • August 8th, 2014 • Fibrogen Inc • Pharmaceutical preparations • California
first amended and restated Evaluation AGREEMENT BY AND BETWEEN FIBROGEN, INC. AND FORTIS Therapeutics, INC. JUNE 6, 2024Evaluation Agreement • August 6th, 2024 • Fibrogen Inc • Pharmaceutical preparations • Delaware
This First Amended and Restated Evaluation Agreement (this “Agreement”) is entered into as of June 6, 2024 (the “Restatement Effective Date”) by and between FIBROGEN, INC., a Delaware corporation, with its principal place of business at 409 Illinois Street, San Francisco, California 94158 (“FibroGen”), and FORTIS THERAPEUTICS, INC., having an address at 11099 North Torrey Pines Road, Suite 290, La Jolla, CA 92037 (“Fortis”). FibroGen and Fortis may be referred to herein individually as a “Party”, or collectively as the “Parties”.
Consulting AgreementConsulting Agreement • September 6th, 2023 • Fibrogen Inc • Pharmaceutical preparations • California
This Consulting Agreement (“Agreement”) is effective as of September 11, 2023 (“Effective Date”), by and between FibroGen, Inc., a Delaware corporation with its principal offices located at 409 Illinois Street, San Francisco, California 94158 and its subsidiaries (collectively “FibroGen”) and Mark Eisner, an individual residing at [PRIVATE ADDRESS] (“Consultant”).
Option Agreement and Plan of Merger BY AND among Fibrogen, Inc., Fortis therapeutics, Inc. and SHAREHOLDER REPRESENTATIVE SERVICES LLC, as Sellers’ Representative Dated as of JUNE 6, 2024Option Agreement and Plan of Merger • August 6th, 2024 • Fibrogen Inc • Pharmaceutical preparations
This First Amended and Restated Option Agreement and Plan of Merger (this “Option Agreement”) dated as of June 6, 2024 (the “Restatement Effective Date”) amends and restates that certain Option Agreement and Plan of Merger, effective as of May 5, 2023 (the “Original Effective Date” and such agreement, the “Original Agreement”), by and among FibroGen, Inc., a Delaware corporation (“FibroGen”), Fortis Therapeutics, Inc., a Delaware corporation (“Fortis”), and Shareholder Representative Services LLC, a Colorado limited liability company, solely in its capacity as the Sellers’ Representative.
AMENDMENT NO. 2 TO RESEARCH AND COMMERCIALIZATION AGREEMENTResearch and Commercialization Agreement • October 1st, 2014 • Fibrogen Inc • Pharmaceutical preparations
THIS AMENDMENT NO. 2 TO RESEARCH AND COMMERCIALIZATION AGREEMENT (“Amendment”) is made and entered into effective as of January 28, 2002 (the “Amendment Date”) by and between MEDAREX, INC., 707 State Road, Suite 206, Princeton, NJ 08540, GENPHARM INTERNATIONAL INC., a wholly-owned subsidiary of Medarex, Inc. (together, “Medarex”), and FibroGen, Inc., a Delaware corporation, 225 Gateway Boulevard, South San Francisco, California 94080 and FIBROPHARMA, INC., a wholly-owned subsidiary of FIBROGEN, INC. (collectively, “FibroGen”). Capitalized terms used in this Amendment that are not otherwise defined herein shall have the same meanings as such terms are defined in the Agreement (as defined below).
INVESTOR RIGHTS AGREEMENTInvestor Rights Agreement • June 11th, 2014 • Fibrogen Inc • Pharmaceutical preparations • Delaware
INVESTOR RIGHTS AGREEMENT (the “Agreement”) made and entered into as of February 20, 1998, by and among FIBROGEN, INC., a Delaware corporation (the “Company”), and the parties who have executed this Agreement as Investors (the “Investors”).
Amendment No. 29 to the Process Development and Clinical Supply AgreementProcess Development and Clinical Supply Agreement • March 1st, 2017 • Fibrogen Inc • Pharmaceutical preparations
This Amendment No. 29 (the “29th Amendment”), effective as of December 20, 2016 (the “29th Amendment Effective Date”) by and between Boehringer Ingelheim Biopharmaceuticals GmbH, Binger Str. 173, 55216 Ingelheim, Germany (“BI”) and FibroGen, Inc., 409 Illinois Street, San Francisco, CA 94158, USA (“FibroGen”), amends the Process Development and Clinical Supply Agreement entered into by and between Boehringer Ingelheim Pharma GmbH & Co. KG, Birkendorfer Str. 65, 88397 Biberach an der Riss, Germany (“BI Pharma”) and on November 29, 2007, as amended pursuant to the letter agreements entered into as of June 26, 2008 and August 18, 2008, Amendment No. 1, effective as of May 28, 2009, Amendment No. 3, effective as of November 5, 2010, Amendment No. 4, effective as of January 24, 2011, Amendment No. 5, effective as of April 15, 2011, Amendment No. 6, effective as of May 26, 2011, Amendment No. 7, effective as of January 01, 2012, Amendment No. 8, effective as of July 10, 2012, Amendment No. 9
Amendment No. 3 To Master Supply AgreementMaster Supply Agreement • May 10th, 2021 • Fibrogen Inc • Pharmaceutical preparations
This Amendment No. 3 (the “Third Amendment”) is entered into as of January 12, 2021, and effective as of October 1, 2020 (the “Third Amendment Effective Date”) by and among: FibroGen, Inc. and its Affiliates (collectively, “FibroGen”); and Shanghai SynTheAll Pharmaceutical Co., Ltd (d/b/a “上海合全药业有限公司”) (“Shanghai STA”); and STA Pharmaceutical Hong Kong Limited (d/b/a “合全药业香港有限公司”) (“STA Hong Kong”) (STA Hong Kong, Shanghai STA, and each of their Affiliates are collectively referred to as “STA”). This Third Amendment amends the Master Supply Agreement entered into by and between STA and FibroGen on March 2, 2020 (the “Master Supply Agreement”), as amended by Amendment No. 1 on May 11, 2020 and Amendment No.2 on July 24, 2020 (collectively, the “Prior Amendments”). STA and FibroGen shall be referred to individually herein as a “Party”, and collectively as, the “Parties”. The Master Supply Agreement, the Prior Amendments, and this Third Amendment are collectively, the “Agreement”.
LICENSE AGREEMENTLicense Agreement • June 11th, 2014 • Fibrogen Inc • Pharmaceutical preparations • Florida
This Agreement, made and entered into this 23rd day of May, 1997 (the Effective Date”), by and between the UNIVERSITY OF MIAMI and its SCHOOL OF MEDICINE, having its principal office at 1600 N.W. 10th Avenue, Miami, Florida 33136 (hereinafter “LICENSOR”) and FIBROGEN, INC., a corporation duly organized under the laws of Delaware and having its principal office at 260 Littlefield Avenue, South San Francisco, California 94080 and its Affiliates (hereinafter collectively, “FIBROGEN”).
MASTER SUPPLY AGREEMENTMaster Supply Agreement • November 5th, 2020 • Fibrogen Inc • Pharmaceutical preparations
This Master Supply Agreement (the “Agreement”) is entered into and effective as of September 10, 2020 (the “Effective Date”), by and between FibroGen, Inc., a Delaware corporation, having its principal place of business at 409 Illinois Street, San Francisco, California 94158, United States of America (“FibroGen”); and AstraZeneca UK Limited., a company incorporated in England under No. 364842 whose registered office is at 1 Francis Crick Avenue, Cambridge Biomedical Campus CB2 0AA, England (“AstraZeneca”). AstraZeneca and FibroGen may be referred to individually as a “Party”, and collectively as the “Parties”. AstraZeneca and each of its Affiliates shall collectively be referred to herein as “AstraZeneca”. FibroGen and each of its Affiliates shall collectively be referred to herein as “FibroGen”.
Amendment No. 32 to the Process Development and Clinical Supply AgreementProcess Development and Clinical Supply Agreement • February 27th, 2018 • Fibrogen Inc • Pharmaceutical preparations
This Amendment No. 32 (the “32nd Amendment”), effective as of September 1, 2017 (the “32nd Amendment Effective Date”) by and between Boehringer Ingelheim Biopharmaceuticals GmbH, Binger Str. 173, 55216 Ingelheim, Germany (“BI”) and FibroGen, Inc., 409 Illinois Street, San Francisco, CA 94158, USA (“FibroGen”), amends the Process Development and Clinical Supply Agreement entered into by and between Boehringer Ingelheim Pharma GmbH & Co. KG, Birkendorfer Str. 65, 88397 Biberach an der Riss, Germany (“BI Pharma”) and FibroGen on November 29, 2007, as amended pursuant to the letter agreements entered into as of June 26, 2008 and August 18, 2008, Amendment No. 1, effective as of May 28, 2009, Amendment No. 3, effective as of November 5, 2010, Amendment No. 4, effective as of January 24, 2011, Amendment No. 5, effective as of April 15, 2011, Amendment No. 6, effective as of May 26, 2011, Amendment No. 7, effective as of January 01, 2012, Amendment No. 8, effective as of July 10, 2012, Amendm
Amendment No. 30 to the Process Development and Clinical Supply AgreementProcess Development and Clinical Supply Agreement • March 1st, 2017 • Fibrogen Inc • Pharmaceutical preparations
This Amendment No. 30 (the “30th Amendment”), effective as of December 20, 2016 (the “30th Amendment Effective Date”) by and between Boehringer Ingelheim Biopharmaceuticals GmbH, Binger Str. 173, 55216 Ingelheim, Germany (“BI”) and FibroGen, Inc., 409 Illinois Street, San Francisco, CA 94158, USA (“FibroGen”), amends the Process Development and Clinical Supply Agreement entered into by and between Boehringer Ingelheim Pharma GmbH & Co. KG, Birkendorfer Str. 65, 88397 Biberach an der Riss, Germany (“BI Pharma”) and on November 29, 2007, as amended pursuant to the letter agreements entered into as of June 26, 2008 and August 18, 2008, Amendment No. 1, effective as of May 28, 2009, Amendment No. 3, effective as of November 5, 2010, Amendment No. 4, effective as of January 24, 2011, Amendment No. 5, effective as of April 15, 2011, Amendment No. 6, effective as of May 26, 2011, Amendment No. 7, effective as of January 01, 2012, Amendment No. 8, effective as of July 10, 2012, Amendment No. 9
ContractProcess Development and Clinical Supply Agreement • September 24th, 2014 • Fibrogen Inc • Pharmaceutical preparations
[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.
CHANGE IN CONTROL AND SEVERANCE AGREEMENTChange in Control and Severance Agreement • March 2nd, 2020 • Fibrogen Inc • Pharmaceutical preparations • California
This Change in Control and Severance Agreement (this “Agreement”) is dated as of ____________ (the “Effective Date”), by and between [______________] (“Executive”) and FibroGen, Inc., a Delaware corporation (the “Company”). This Agreement is intended to provide Executive with certain benefits described herein upon the occurrence of specific events.
ASTELLAS EU SUPPLY AGREEMENTSupply Agreement • May 10th, 2021 • Fibrogen Inc • Pharmaceutical preparations
This Astellas EU Supply Agreement (the “Agreement”) is effective as of January 1, 2021 (the “Effective Date”), by and between: FibroGen, Inc., a Delaware corporation with offices located at 409 Illinois Street, San Francisco, California 94158 U.S.A. (“FibroGen”); and Astellas Pharma Europe Ltd, an English corporation with offices located at 300 Dashwood Lang Road, Bourne Business Park, Addlestone, Surrey, KT15 2NX England (“Astellas”). Astellas and FibroGen may be referred to individually as a “Party”, and collectively as the “Parties”. Astellas and each of its Affiliates shall collectively be referred to herein as “Astellas”. FibroGen and each of its Affiliates shall collectively be referred to herein as “FibroGen”.
Amendment No. 25 to the Process Development and Clinical Supply AgreementProcess Development and Clinical Supply Agreement • August 8th, 2016 • Fibrogen Inc • Pharmaceutical preparations
This Amendment No. 25 (the “25th Amendment”), retroactively effective as of October 15, 2015 (the “25th Amendment Effective Date”) by and between Boehringer Ingelheim Biopharmaceuticals GmbH, Binger Str. 173, 55216 Ingelheim, Germany (“BI”) and FibroGen, Inc., 409 Illinois Street, San Francisco, CA 94158, USA (“”), amends the Process Development and Clinical Supply Agreement entered into by and between Boehringer Ingelheim Pharma GmbH & Co. KG, Birkendorfer Str. 65, 88397 Biberach an der Riss, Germany (“BI Pharma”) and on November 29, 2007, as amended pursuant to the letter agreements entered into as of June 26, 2008 and August 18, 2008, Amendment No. 1, effective as of May 28, 2009, Amendment No. 3, effective as of November 5, 2010, Amendment No. 4, effective as of January 24, 2011, Amendment No. 5, effective as of April 15, 2011, Amendment No. 6, effective as of May 26, 2011, Amendment No. 7, effective as of January 01, 2012, Amendment No. 8, effective as of July 10, 2012, Amendment
AMENDMENT NO. 12 TO THE PROCESS DEVELOPMENT AND CLINICAL SUPPLY AGREEMENTProcess Development and Clinical Supply Agreement • October 1st, 2014 • Fibrogen Inc • Pharmaceutical preparations
THIS AMENDMENT NO. 12 (the “Twelfth Amendment”), effective as of August 01, 2013 (the “Twelfth Amendment Effective Date”) by and between Boehringer Ingelheim Pharma GmbH & Co. KG, Birkendorfer Straße 65, 88397 Biberach an der Riss, Germany (“BI Pharma”) and FibroGen, Inc., 409 Illinois Street, San Francisco, CA 94158, USA (“FibroGen”), amends the Process Development and Clinical Supply Agreement entered into by and between BI Pharma and FibroGen on November 29, 2007, as amended pursuant to the letter agreements entered into as of June 26, 2008 and August 18, 2008, Amendment No. 1, effective as of May 28, 2009, Amendment No. 3, effective as of November 5, 2010, Amendment No. 4, effective as of January 24, 2011, Amendment No. 5, effective as of April 15, 2011, Amendment No. 6, effective as of May 26, 2011, Amendment No. 7, effective as of January 01, 2012, Amendment No. 8, effective as of July 10, 2012, Amendment No. 9, effective as of November 26, 2012, Amendment No. 10, effective as of
FIBROGEN, INC. STOCK OPTION AGREEMENT (INCENTIVE STOCK OPTION OR NONSTATUTORY STOCK OPTION)Stock Option Agreement • October 1st, 2014 • Fibrogen Inc • Pharmaceutical preparations
Pursuant to your Stock Option Grant Notice (“Grant Notice”) and this Stock Option Agreement, FibroGen, Inc. (the “Company”) has granted you an option under its 2005 Stock Plan (the “Plan”) to purchase the number of shares of the Company’s Common Stock indicated in your Grant Notice at the exercise price indicated in your Grant Notice. Defined terms not explicitly defined in this Stock Option Agreement but defined in the Plan shall have the same definitions as in the Plan.
FIBROGEN, INC. STOCK OPTION AGREEMENT (INCENTIVE STOCK OPTION OR NONSTATUTORY STOCK OPTION)Stock Option Agreement • October 1st, 2014 • Fibrogen Inc • Pharmaceutical preparations
Pursuant to your Election to Participate in FibroGen’s Amendment and Exchange Offer ending on June 24, 2010 (your “Election”) and this Stock Option Agreement entered into and made effective on June 24, 2010 (the “Agreement”), FibroGen, Inc. (the “Company”) has granted you a new option under its 2005 Stock Plan (the “Plan”) to purchase the number of shares of the Company’s Common Stock not yet exercised from the original stock option grant(s) cancelled by your Election, at the exercise price indicated in your New Stock Option Grant Notice (the “Grant Notice”) which you shall promptly sign and return to the Company after it is distributed to you. Defined terms not explicitly defined in this Stock Option Agreement but defined in the Plan shall have the same definitions as in the Plan.
